Načítá se...
Cost-effectiveness analysis of ixekizumab versus etanercept and their manufacturer recommended dosing regimens in moderate to severe plaque psoriasis
INTRODUCTION: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Food and Drug Administration (FDA) approved ixekizumab for treating psoriasis. Evaluating the cost-eff...
Uloženo v:
| Vydáno v: | J Drugs Dermatol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5802402/ https://ncbi.nlm.nih.gov/pubmed/29036249 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|